Netakimab

Phase 3Monoclonal antibody

SSPH-BIOCAD (HK) Limited

Netakimab is one of 86 small molecule programs targeting Psoriasis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PsoriasisActive, not recruiting

COVID-19Active, not recruiting

Ankylosing SpondylitisActive, not recruiting

PsoriasisPhase 3

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

Ankylosing SpondylitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Netakimab

SSPH-BIOCAD (HK) Limited

Phase 3

1 2

Spikevax

Moderna

Preclinical

21 3

Aimovig

Amgen

Preclinical

1 4

Aldactone

Pfizer

Preclinical

1 5

Nexavar

Bayer

Preclinical

1 6

Orap

Teva

Preclinical

1 7

Biological Data

UUniversity Hospital, Bordeaux

Preclinical

3 8

Selenium

SSWOG Cancer Research Network

Preclinical

1 9

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 10

Interferon-Gamma

SSPP Pharmaclon Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Active, not recruiting

Psoriasis

NCT06640517

Clinical

Trials by Indication[1]

Psoriasis2 trials

Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis

Active, not recruiting·BBiocad·Phase 3·NCT06640517·140 enrolled

To Evaluate the Efficacy and Safety of Netakimab in Chinese Patients With Moderate to Severe Plaque Psoriasis

Active, not recruiting·SSPH-BIOCAD (HK) Limited·Phase 3·NCT07008547·202 enrolled

COVID-191 trial

COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU

Completed·PPirogov Russian National Research Medical University··NCT05302947·154 enrolled

Ankylosing Spondylitis1 trial

Evaluate the Efficacy, Safety, and Pharmacokinetic Profile and Immunogenicity of Subcutaneous Netakimab in Chinese Adult Patients With Active Ankylosing Spondylitis

Completed·SSPH-BIOCAD (HK) Limited·Phase 3·NCT07277179·113 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Netakimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Netakimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Netakimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SPH-BIOCAD (HK) Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: SSPH-BIOCAD (HK) Limited

Netakimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Psoriasis2 trials

COVID-191 trial

Ankylosing Spondylitis1 trial

References

Drug Info

Quick Facts

Related News